Co-Funding. (a) With respect to each Licensed Product, Novartis shall, during the Exclusivity Term, provide timely notice to Alnylam before the initiation of the first Phase I Study with respect to such Licensed Product.
(b) Alnylam will thereafter have a period of no more than [**] to provide written notice to Novartis of Alnylam's interest in co-funding, and sharing in the net profits and losses of, Novartis's Development and Commercialization of such Licensed Product ("Co-Fund" or "Co-Funding"). Such Co-Funding shall be in lieu of receiving the payments described in Section 4.4 with respect to such Licensed Product, and shall include a premium for Novartis's risks to date.
(c) If Novartis has an interest in having Alnylam Co-Fund such Licensed Product, the Parties shall enter into good faith negotiations for a period of [**] after receipt of Alnylam's notice of interest (the "Co-Fund Negotiation Period") to determine whether or not, and if so, the terms and conditions (including financial terms and observer rights) pursuant to which, Alnylam may Co-Fund such Licensed Product. If the Parties are for any reason unable to enter into a written Co-Funding agreement during the Co-Fund Negotiation Period with respect to such Licensed Product, Novartis shall be free to continue Developing and Commercializing such Licensed Product without any further obligation under this Section 4.6 to Alnylam; provided, however, the Parties shall during the course of this Agreement agree to enter into [**] Co-Funding agreements with respect to [**] Collaboration Products.
(d) Alnylam's Co-Funding of a Collaboration Product, if agreed to by the Parties pursuant to Section 4.6(c), shall provide that Alnylam: (i) shall be required to fund at least [**] percent ([**]%) of Novartis's past and future development and commercialization costs and expenses of such Collaboration Product, and (ii) shall share in at least [**] percent ([**]%) of the net profits and losses of the development and commercialization of such Collaboration Product.
(e) For avoidance of doubt, Alnylam's Co-Funding of a Licensed Product shall not give Alnylam any additional decision-making rights and Novartis will be solely responsible for all decisions regarding the Development and Commercialization of such Co-Funded Licensed Product.
Co-Funding. (a) The Recipient must secure and use at least the following financial contributions (“Co-Funding”) solely and specifically to undertake and meet the costs of the Activities. The Recipient’s financial contribution includes in-kind contributions (including internal staff time) spent on undertaking the Activities, provided that the in-kind contribution is valued in accordance with this Agreement. [insert] $[insert] [optional: (In-kind) (cash)] [insert] $[insert] [optional: (In-kind) (cash)] [insert] $[insert] [optional: (In-kind) (cash)]
(b) The Recipient must provide ACC with written evidence:
(i) that the Recipient has secured the Co-Funding; and
(ii) of the terms of the Co-Funding, including:
a. the amounts to be provided;
b. the due date for payment of the amounts; and
c. any other terms and conditions of the provision of the Co-Funding, which must be satisfactory to ACC, acting reasonably.
(c) The Recipient must notify ACC in writing within 14 days:
(i) after entering into any arrangement under which it is entitled to receive any financial or in-kind contributions to the Activities which are not specified above; and
(ii) of the Recipient becoming aware of any circumstances that may result in any Co-Funding not being provided.
Co-Funding. If specified at item 11 of the Key Details, the Recipient must:
Co-Funding. 5.1 Co-Funding is specified in item 8 of Schedule 1, the Recipient must:
(a) ensure that during the term of this Agreement the Co-Funding is and remains secured and available to the Recipient to be applied towards the Project; and
(b) immediately notify EECA if it becomes aware of any circumstances that may result in the Co-Funding (or any part of the Co-Funding) not being secured and available to the Recipient to be applied towards the Project.
5.2 The Recipient must contribute the Co-Funding to satisfy the Project completion.
5.3 The Recipient undertakes to pay the Co-Funding (if any) and any and all cost overruns of the Project, and any funding shortfall, and acknowledges that EECA and the New Zealand Government have no obligations or responsibility whatsoever in respect of such Co-Funding, cost overruns or funding shortfalls.
Co-Funding. The Recipient is not required to contribute co-funding, however if any is received it will be reported on (item 12).
Co-Funding. The Recipient must:
Co-Funding. The Course Provider may obtain further separate sources of funding to subsidise a portion of the Course Fees payable by the Trainee, provided:
(a) Such separate sources do not originate (whether directly or indirectly) from the Course Provider, any of its related and/or associated companies or the Government of Singapore / Organs of State / other statutory boards. (For the purposes of this paragraph, a company is related to the Course Provider if the relationship between them comes within the ambit of Section 6 of the Companies Act (Cap 50); and a company is taken to be associated with the Course Provider if that company is a joint venture partner of the Course Provider or if either party has an interest in the shares (within the meaning of section 7 of the Companies Act (Cap 50)) of the other party;
(b) The Claim Applicant must still continue to pay a portion of the Course Fees; and
(c) Prior written approval has been obtained from IMDA.
Co-Funding. If the JSC approves the Additional Study pursuant to Section 5.3.1(d) and the Non-Proposing Party agrees to co-fund such Additional Study, then the Parties shall amend the Development Plan to include such Additional Study in accordance with Section 2.2.2, and the costs of such Additional Study shall be included in the Development Cost shared by the Parties in accordance with Section 2.2.3.
Co-Funding. The Recipient must have contributed the following Co-Funding to the Project: Commercial Information excluding GST (if any) from the Recipient excluding GST (if any) from the Recipient excluding GST (if any) from the Recipient
Co-Funding. 2.1 The Recipient must ensure that during the term of this Agreement the Co-Funding:
(i) is and remains secured and available to the Recipient to be applied towards the Project on the same terms and conditions approved by the Ministry; and
(ii) is applied to Eligible Costs as set out in the Key Details.
2.2 NLTF co-funding is expected for the Project Deliverables as outlined in Schedule One. The Recipient will work with the NZTA to support the NLTF funding approval process, including but not limited to business case requirements.
2.3 The Recipient must immediately notify the Ministry if it becomes aware of any circumstances that may result in the Co-Funding or the NLTF co-funding (or any part of the NLTF co-funding) not being secured and available to the Recipient to be applied towards the Project.
